Berdazimer sodium - SB 019 - Ligand Pharmaceuticals
Alternative Names: Berdazimer sodium - SB-019; MAP3-NONOate; SB-019Latest Information Update: 11 Jan 2024
Price :
$50 *
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Novan Inc
- Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Esters; Macromolecular substances; Nitrogen oxides; Nitroso compounds; Non-opioid analgesics; Propylamines; Silicates; Silicon compounds; Skin disorder therapies; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Nitric oxide donors; NLRP3 protein inhibitors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended COVID 2019 infections
Most Recent Events
- 31 Dec 2023 Novan plans a phase II/III trial for COVID-2019 infections (Intranasal), in 2023
- 27 Sep 2023 Ligand Pharmaceuticals acquires the rights of all the assets related to the NITRICIL technology platform from Novan
- 31 May 2023 Suspended - Preclinical for COVID-2019 infections in USA (Intranasal), before May 2023